Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
Abstract Objective This paper aimed to assess the clinical efficacy, adverse reactions, and safety of employing PD-1 inhibitors in conjunction with chemotherapy as a treatment strategy for advanced gastric cancer (GC). Methods Ninety patients with advanced GC from January 2020 to December 2021 were...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-11-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-023-03011-y |
| _version_ | 1797636831071698944 |
|---|---|
| author | Xue Huang Du He Lin Lai Jun Chen Yukun Zhang Huilin Mao |
| author_facet | Xue Huang Du He Lin Lai Jun Chen Yukun Zhang Huilin Mao |
| author_sort | Xue Huang |
| collection | DOAJ |
| description | Abstract Objective This paper aimed to assess the clinical efficacy, adverse reactions, and safety of employing PD-1 inhibitors in conjunction with chemotherapy as a treatment strategy for advanced gastric cancer (GC). Methods Ninety patients with advanced GC from January 2020 to December 2021 were divided into the research group (n = 45) and the control group (n = 45). The control group was treated with apatinib and tigio. The study group was treated with PD-1 inhibitor combined with apatinib and tigio. The remission rate (RR), disease control rate (DCR), overall survival (OS), Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) score, EORTCQLQ-C30 (v3.0) score, and incidence of adverse reactions were compared between the two groups. Results The research group exhibited improved outcomes in several key metrics relative to the control group. Specifically, the RR, DCR, and OS were notably higher in the research group. Additionally, the ECOG-PS score was significantly reduced, indicating better performance. At a median follow-up of 8.7 months, the research group’s functional and total health scores on the EORTC QLQ-C30 (v3.0) scale had seen significant improvement compared to their initial scores and were also superior to the control group’s scores. Importantly, both groups demonstrated comparable incidence rates for adverse reactions, with no significant difference observed (P > 0.05). Conclusion PD-1 inhibitor combined with chemotherapy was more effective when treating patients with advanced GC. It was more beneficial to enhance the patient’s condition, promote survival time, and improve physical status and life quality. In addition, the adverse reactions could be controlled. |
| first_indexed | 2024-03-11T12:40:51Z |
| format | Article |
| id | doaj.art-947a0f68f196481caf8f1c076a2de36a |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-03-11T12:40:51Z |
| publishDate | 2023-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-947a0f68f196481caf8f1c076a2de36a2023-11-05T12:19:49ZengBMCBMC Gastroenterology1471-230X2023-11-012311810.1186/s12876-023-03011-yEvaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancerXue Huang0Du He1Lin Lai2Jun Chen3Yukun Zhang4Huilin Mao5Department of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central HospitalDepartment of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central HospitalDepartment of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central HospitalDepartment of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central HospitalDepartment of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central HospitalDepartment of Pediatric Surgery, Enshi Tujia and Miao Autonomous Prefecture Central HospitalAbstract Objective This paper aimed to assess the clinical efficacy, adverse reactions, and safety of employing PD-1 inhibitors in conjunction with chemotherapy as a treatment strategy for advanced gastric cancer (GC). Methods Ninety patients with advanced GC from January 2020 to December 2021 were divided into the research group (n = 45) and the control group (n = 45). The control group was treated with apatinib and tigio. The study group was treated with PD-1 inhibitor combined with apatinib and tigio. The remission rate (RR), disease control rate (DCR), overall survival (OS), Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) score, EORTCQLQ-C30 (v3.0) score, and incidence of adverse reactions were compared between the two groups. Results The research group exhibited improved outcomes in several key metrics relative to the control group. Specifically, the RR, DCR, and OS were notably higher in the research group. Additionally, the ECOG-PS score was significantly reduced, indicating better performance. At a median follow-up of 8.7 months, the research group’s functional and total health scores on the EORTC QLQ-C30 (v3.0) scale had seen significant improvement compared to their initial scores and were also superior to the control group’s scores. Importantly, both groups demonstrated comparable incidence rates for adverse reactions, with no significant difference observed (P > 0.05). Conclusion PD-1 inhibitor combined with chemotherapy was more effective when treating patients with advanced GC. It was more beneficial to enhance the patient’s condition, promote survival time, and improve physical status and life quality. In addition, the adverse reactions could be controlled.https://doi.org/10.1186/s12876-023-03011-yPD-1 inhibitorChemotherapyAdvanced gastric cancerEfficacyLife qualityAdverse reactions |
| spellingShingle | Xue Huang Du He Lin Lai Jun Chen Yukun Zhang Huilin Mao Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer BMC Gastroenterology PD-1 inhibitor Chemotherapy Advanced gastric cancer Efficacy Life quality Adverse reactions |
| title | Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| title_full | Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| title_fullStr | Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| title_full_unstemmed | Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| title_short | Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| title_sort | evaluation of clinical efficacy adverse reactions and safety of pd 1 inhibitors combined with chemotherapy when treating advanced gastric cancer |
| topic | PD-1 inhibitor Chemotherapy Advanced gastric cancer Efficacy Life quality Adverse reactions |
| url | https://doi.org/10.1186/s12876-023-03011-y |
| work_keys_str_mv | AT xuehuang evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer AT duhe evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer AT linlai evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer AT junchen evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer AT yukunzhang evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer AT huilinmao evaluationofclinicalefficacyadversereactionsandsafetyofpd1inhibitorscombinedwithchemotherapywhentreatingadvancedgastriccancer |